Influenza Therapeutics Market: Regional Analysis
On the basis of region, the global influenza therapeutics market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America holds dominant position in the market, owing to high presence of key players
such as GlaxoSmithKline plc and Hoffmann-La Roche Ltd. The regulatory agencies in the region
select influenza viruses that are required for developing the influenza vaccine. In March 2018,
FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) conducted a
meeting to select the influenza viruses for the composition of the influenza vaccine. In the
meeting, VRBPAC recommended the trivalent formulation of influenza vaccines for influenza A
including A/Michigan/45/2015 (H1N1) pdm09-like virus, A/Singapore/INFIMH-16–0019/2016
(H3N2)-like virus, and B/Colorado/06/2017-like virus (B/Victoria lineage). The committee also
recommended that quadrivalent influenza vaccines contain the above three strains and the
following additional B strain: a B/Phuket/3073/2013-like virus (B/Yamagata lineage).
Inquire Here Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/2443
Asia Pacific is also expected to witness significant growth in the influenza therapeutics market,
owing to increasing initiatives by the Asia-Pacific Alliance for the Control of Influenza (APACI),
to reduce the burden of influenza by enhancing control measures and boosting pandemic
preparedness in the region, through the provision of educational information and activities.
Europe have also gained significant position in the market, owing to increasing initiatives by
European Medical Association (EMA) during an influenza pandemic season leading to
continuous monitoring of safety of centrally authorized pandemic influenza vaccines and
antiviral medicines, and fast-track review of data for the authorization of pandemic influenza
vaccines for use in all EU Member States. Also, increasing number of public awareness
programs for the prevention and diagnosis of influenza resulted in significant growth of the
influenza therapeutics market in this region.
Key players operating in the global influenza therapeutic market include Daiichi Sankyo
Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical
Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd.,
BiondVax Pharmaceuticals Ltd., Atriva Therapeutics Gmbh, Texas Medical Center, Life Science
Austria (LISA), GE Healthcare Life Sciences, Sanofi Pasteur SA and Mylan, Inc.